{
  "Country": "EN",
  "PICOs": [
    {
      "Population": "Adults with KRAS G12C mutation-positive, locally advanced or metastatic non-small-cell lung cancer who have previously been treated",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Overall survival, progression-free survival, objective response rate"
    },
    {
      "Population": "Adults with KRAS G12C mutation-positive, locally advanced or metastatic non-small-cell lung cancer who have previously been treated",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel plus nintedanib",
      "Outcomes": "Overall survival, progression-free survival, objective response rate"
    },
    {
      "Population": "Adults with KRAS G12C mutation-positive, locally advanced or metastatic non-small-cell lung cancer who have previously been treated",
      "Intervention": "New medicine under assessment",
      "Comparator": "Platinum-doublet chemotherapy",
      "Outcomes": "Overall survival, progression-free survival, objective response rate"
    }
  ]
}